Our strategy is to drive research for the benefit of patients affected by cancer and by inherited disease in Wales and beyond, and at all points in the patient pathway - from prevention through screening, diagnosis, imaging, tissue studies, and clinical trials.
The Institute of Cancer & Genetics brings together researchers to promote translational research, employing model systems to develop new cancer therapeutics and diagnostics and take them through to the clinic. Covering molecular/cellular biology through to cancer trials there are collaborative links with researchers in the Welsh School of Pharmacy and Cardiff School of Biosciences and also the newly established Cardiff CRUK Cancer Centre. For more information on our research please visit our Research in the Institute of Cancer & Genetics page.
The Institute of Cancer & Genetics is a merger of the Institute of Medical Genetics and sections of Oncology, Surgery, Pathology, Haematology, and Gynaecology Oncology.
- October 2013
Distinguished immunologist visits Cardiff for annual memorial lecture
16th October 2013Prof Philippa Marrack from the University of Colorado (Denver, USA) gives a motivating and inspiring Jonathan Boulter Memorial Lecture 2013
Cardiff scientist wins prestigious national prize
8th October 2013Dr Elisabeth Walsby, a senior postdoctoral scientist working in the Cardiff CLL research group within the School of Medicine, was awarded the 2013 Catovsky Prize at a recent meeting of …
- Distinguished immunologist visits Cardiff for annual memorial lecture
- September 2013
Cardiff-Peking universities cancer breakthrough - BBC
28th September 2013Combining traditional forms of Chinese and Western medicine could offer new hope for developing new treatments for some cancers, say experts from universities in Cardiff and Peking.
- Cardiff-Peking universities cancer breakthrough - BBC
- January 2014
- February 2014
- Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy.
Al-Taei S et al, Cancer Immunol Immunother
- Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling.
Hole PS et al, Blood
- Receptor-like protein tyrosine phosphatase κ negatively regulates the apoptosis of prostate cancer cells via the JNK pathway.
Sun PH et al, Int J Oncol